Concord Biotech Faces Technical Shift Amid Declining Sales and Profit Metrics
Concord Biotech has experienced a recent evaluation adjustment due to shifts in its technical indicators. The company reported a decline in net sales and profits in the latest quarter, highlighting growth challenges. Despite this, it maintains strong long-term fundamentals and a solid financial position with low debt.
Concord Biotech, a midcap player in the Pharmaceuticals & Drugs industry, has recently undergone an adjustment in evaluation, reflecting changes in its underlying technical indicators. The stock's technical trend has shifted, indicating a more cautious outlook based on various metrics. In the latest quarter, the company reported net sales of Rs 244.22 crore, which represents a decline compared to the previous four-quarter average. Additionally, profit before tax and profit after tax also showed reductions, suggesting challenges in maintaining growth momentum. Despite these recent figures, Concord Biotech has demonstrated a strong long-term fundamental strength, with an average return on equity of 20.62% and a healthy operating profit growth rate of 30.13% annually.
The stock's technical indicators, including MACD and Bollinger Bands, are currently in a bearish range, which has contributed to the recent revision in its score. The company maintains a low debt-to-equity ratio, indicating a solid financial position.
For those interested in tracking the evolving financial landscape of Concord Biotech, further insights can be found here: Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
